HRMY
Harmony Biosciences Holdings, Inc. NASDAQ$32.34
Pre-mkt
$32.95
+1.89%
Mkt Cap $1.9B
52w Low $25.52
44.4% of range
52w High $40.87
50d MA $28.91
200d MA $32.97
P/E (TTM)
11.5x
EV/EBITDA
6.4x
P/B
2.1x
Debt/Equity
0.3x
ROE
18.2%
P/FCF
6.2x
RSI (14)
—
ATR (14)
—
Beta
0.89
50d MA
$28.91
200d MA
$32.97
Avg Volume
956.2K
About
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | AMC | 0.84 | 0.38 | -54.8% | 28.19 | -1.1% | +0.0% | +3.1% | +1.2% | +2.5% | +0.3% | — |
| Nov 4, 2025 | AMC | 0.92 | 0.87 | -5.4% | 30.72 | -1.3% | +2.1% | +0.7% | +2.3% | +3.6% | +7.4% | — |
| Aug 5, 2025 | AMC | 0.78 | 0.68 | -12.8% | 34.94 | +0.8% | -0.8% | -2.1% | -2.1% | -0.4% | +1.5% | — |
| May 6, 2025 | AMC | 0.59 | 0.78 | +32.2% | 32.05 | +0.5% | +4.3% | +6.4% | +6.2% | +11.2% | +7.2% | — |
| Feb 25, 2025 | AMC | 0.74 | 0.85 | +14.9% | 36.97 | -2.5% | -9.5% | -11.4% | -8.4% | -13.0% | -11.8% | — |
| Oct 29, 2024 | AMC | 0.67 | 0.79 | +17.9% | 41.49 | -9.6% | -18.5% | -22.6% | -20.3% | -20.3% | -19.5% | — |
| Aug 6, 2024 | AMC | -0.06 | 0.20 | +433.3% | 32.83 | +0.9% | +2.2% | +3.5% | +3.1% | +1.8% | +6.9% | — |
| Apr 30, 2024 | AMC | 0.60 | 0.67 | +11.7% | 30.91 | -1.6% | -2.1% | +2.5% | +2.1% | -0.0% | +1.5% | — |
| Feb 22, 2024 | AMC | 0.48 | 0.45 | -6.2% | 31.45 | -1.1% | +3.3% | +3.2% | +6.5% | +5.8% | +2.1% | — |
| Oct 31, 2023 | AMC | 0.65 | 0.75 | +15.4% | 23.54 | +1.6% | +4.2% | +4.6% | +10.1% | +5.9% | +3.4% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25 | UBS | Maintains | Neutral → Neutral | — | $28.19 | $27.89 | -1.1% | +0.0% | +3.1% | +1.2% | +2.5% | +0.3% |
| Feb 25 | BofA Securities | Maintains | Underperform → Underperform | — | $28.19 | $27.89 | -1.1% | +0.0% | +3.1% | +1.2% | +2.5% | +0.3% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.19 | $27.89 | -1.1% | +0.0% | +3.1% | +1.2% | +2.5% | +0.3% |
| Feb 25 | Needham | Maintains | Buy → Buy | — | $28.19 | $27.89 | -1.1% | +0.0% | +3.1% | +1.2% | +2.5% | +0.3% |
| Feb 11 | UBS | Downgrade | Buy → Neutral | — | $37.93 | $37.08 | -2.2% | -3.5% | -5.5% | -5.1% | -2.7% | -7.0% |
| Jan 8 | Truist | Maintains | Buy → Buy | — | $37.55 | $37.55 | +0.0% | +0.9% | +2.7% | +1.9% | -4.8% | -4.0% |
| Dec 1 | Mizuho | Maintains | Outperform → Outperform | — | $35.29 | $35.60 | +0.9% | +0.6% | +2.0% | +4.8% | +8.4% | +12.9% |
| Nov 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.31 | $34.50 | +0.6% | +2.8% | +3.0% | +3.6% | +2.9% | +3.5% |
| Nov 24 | Needham | Maintains | Buy → Buy | — | $34.31 | $34.50 | +0.6% | +2.8% | +3.0% | +3.6% | +2.9% | +3.5% |
| Nov 6 | Mizuho | Maintains | Outperform → Outperform | — | $31.35 | $31.50 | +0.5% | -1.3% | +0.3% | +1.5% | +5.2% | +7.0% |
Recent Filings
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Harmony's leadership transition to a new CFO could signal strategic shifts in financial management and capital allocation, potentially affecting investor confidence and operational direction.
Apr 14
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Leadership transitions at Harmony create execution risk and potential disruption, requiring investors to assess whether new management can maintain operational momentum and shareholder value.
Apr 2
8-K
Harmony Biosciences Holdings, Inc. -- 8-K Filing
I cannot provide a meaningful analysis as the summary lacks substantive information about the actual business event or transaction disclosed in this 8-K filing.
Feb 24
Data updated apr 25, 2026 2:02pm
· Source: massive.com